Mortality associated with carbapenem-susceptible and Verona Integron-encoded Metallo-β-lactamase-positive Pseudomonas aeruginosa bacteremia by Persoon, M.C. (Marjolein C.) et al.
RESEARCH Open Access
Mortality associated with carbapenem-
susceptible and Verona Integron-encoded
Metallo-β-lactamase-positive Pseudomonas
aeruginosa bacteremia
Marjolein C. Persoon1†, Anne F. Voor in’t holt1†, Cornelia C. H. Wielders2, Diederik Gommers3, Margreet C. Vos1 and
Juliëtte A. Severin1*
Abstract
Background: Studies on various Gram-negative bacteria suggest that resistance to carbapenem antibiotics is responsible
for increased mortality in patients; however, results are not conclusive. We first assessed the 28-day in-hospital all-cause
mortality in patients with Verona Integron-encoded Metallo-β-lactamase-positive Pseudomonas aeruginosa (VIM-PA)
bacteremia compared to patients with VIM-negative, carbapenem-susceptible P. aeruginosa (CS-PA) bacteremia. Second, we
identified determinants for mortality and survival.
Methods: All patients with a positive blood culture with VIM-PA or CS-PA between January 2004 and January 2016 were
included. Kaplan-Meier survival curves were constructed, and survivors and non-survivors were compared on relevant clinical
parameters using univariate analyses, and multivariable analyses using a Cox-proportional hazard model.
Results: In total, 249 patients were included, of which 58 (23.3%) died. Seventeen out of 40 (42.5%) patients with VIM-PA
died, compared to 41 out of 209 (19.6%) patients with CS-PA (difference = 22.9%, P-value = 0.001). Assumed acquisition of
the bacterium at the intensive care unit was significantly associated with mortality (HR = 3.32, 95%CI = 1.60–6.87), and having
had adequate antibiotic therapy in days 1–14 after the positive blood culture was identified as a determinant for survival
(HR = 0.03, 95%CI = 0.01–0.06). VIM-PA vs CS-PA was not identified as an independent risk factor for mortality.
Conclusions: The crude mortality rate was significantly higher in patients with a VIM-PA bacteremia compared to patients
with a CS-PA bacteremia; however, when analyzing the data in a multivariable model this difference was non-significant.
Awareness of the presence of P. aeruginosa in the hospital environment that may be transmitted to patients and rapid
microbiological diagnostics are essential for timely administration of appropriate antibiotics. Acquisition of P. aeruginosa
should be prevented, independent of resistance profile.
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Introduction
Studies suggest that infections with microorganisms re-
sistant to carbapenem antibiotics may be responsible for
increased mortality in patients compared to infections
with susceptible microorganisms [1, 2]. However, results
are not conclusive and evidence is limited; attributable
mortality is therefore still the subject of ongoing investi-
gations [3].
Carbapenem resistance in Pseudomonas aeruginosa iso-
lates is an emerging problem, with nosocomial outbreaks
of this microorganism occurring worldwide, also in the
Netherlands [4–6]. In P. aeruginosa isolates, carbapenem
resistance may be caused by a variety of mechanisms.
However, of particular concern is the production of
metallo-beta-lactamase (MBL) enzymes catalyzing the hy-
drolysis of all classes of beta-lactam antibiotics except
monobactams [7]. Currently, the Verona Integron-
encoded MBL (VIM) is the most widespread MBL in P.
aeruginosa, with VIM-2 being the major source of
worldwide outbreaks [8]. Infections (e.g. bacteremia) with
VIM-positive P. aeruginosa (VIM-PA) are mainly seen in
patients with a suppressed immune system or otherwise
compromised, for example in patients admitted to the in-
tensive care unit (ICU) [9]. Published mortality rates for
bloodstream infections with P. aeruginosa are between 20
and 50%, with the rate of carbapenem-resistant P. aerugi-
nosa-attributable deaths among those patients being be-
tween 8 and 18% [2, 10]. However, the question still
remains if mortality in these patients is high because of 1)
inadequate or delayed appropriate antibiotic therapy, 2)
severity of underlying disease, or 3) because of the VIM
gene and the subsequent carbapenem resistance [1, 9, 11,
12]. Moreover, clones with and without carbapenemase
genes can also differ in virulence characteristics, which
could lead to differences in mortality rates between pa-
tients with different clones; independent of the resistant
mechanism [13].
First, we aimed first to compare the 28-day in-hospital all-
cause mortality in patients with a VIM-PA bacteremia to pa-
tients with a bacteremia with VIM-negative, carbapenem-
susceptible P. aeruginosa (CS-PA) in a large tertiary hospital
in the Netherlands. Second, we aimed to identify risk factors
for mortality by P. aeruginosa bacteremia in this setting.
Methods
Ethics statement
Written approval to conduct this study was received
from the medical ethical research committee from the
Erasmus MC University Medical Center (Erasmus MC),
Rotterdam, the Netherlands (MEC-2015-306).
Setting
This study was conducted at the Erasmus MC. During
the study period, this was a 1200-bed university hospital
organized into 48 different wards [14]. Of these wards,
three were high-level adult ICUs, and each had only
single-occupancy rooms. Since 2008 ICU patients
received selective digestive tract decontamination if
expected to be on mechanical ventilation for > 48 h or
anticipated to be admitted to the ICU for > 72 h [15].
The number of clinical admissions and clinical admis-
sion days for the study period are described in a previ-
ous publication [5].
Patient inclusion and data collection
Patients were included if identified with a positive blood
culture with P. aeruginosa between January 1st 2004 and
January 1st 2016. Only the first isolate of each patient
was included. We excluded the following patients: (i) pa-
tients < 18 years old, (ii) non-hospitalized patients, (iii) if
the first positive blood culture contained more than one
pathogenic microorganism, and (iv) patients identified
with a carbapenem-resistant blaVIM-negative P. aerugi-
nosa isolate. Positive blood cultures with both P. aerugi-
nosa and coagulase-negative staphylococci (CoNS) were
included when the CoNS were considered to be contam-
ination. These cultures were excluded if the CoNS was
cultured in a second blood culture and if the CoNS was
considered clinically relevant (e.g. antibiotic treatment
was started or other actions were performed).
We collected the following patient data from the elec-
tronic patient records: (i) age at day of first positive
blood culture with P. aeruginosa, (ii) sex, (iii) date of first
positive blood culture with P. aeruginosa and suscepti-
bility pattern, (iv) department of acquisition, defined as
the department at which the patient was admitted 48 h
before the positive blood culture: if the patient was posi-
tive at admittance this was scored as ‘at home’ or ‘at
other healthcare facility’, (v) date of admission to and
date of discharge from our hospital, (vi) death 28 days
after first positive blood culture yes/no and date of
death, (vii) nosocomial infection, defined as a positive
blood culture with P. aeruginosa > 48 h after admission,
(viii) neutropenia, defined as an absolute neutrophil
count of < 0.5 X109 cells/L during presentation of
bacteremia; neutrophil count was assessed 2 days before
the first positive blood culture was taken to 7 days after-
wards, (ix) use of corticosteroids 28 days before until 28
days after the positive blood culture with P. aeruginosa,
(x) use of other immunosuppressive agents than cortico-
steroids in 28 days before until 28 days after positive
blood culture with P. aeruginosa, and (xi) antibiotic use.
During analyses, viii, ix and x were combined and re-
ported as being immunocompromised yes or no.
Use of one or more of the following antibiotics was
checked from the day the first positive blood culture was
taken to 14 days thereafter: piperacillin/tazobactam, gen-
tamicin, tobramycin, ceftazidime, ciprofloxacin, colistin
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and carbapenems. These antibiotics have antipseudomo-
nal activity and are part of our local antibiotic policy. Pi-
peracillin without tazobactam is not used in our hospital.
Three definitions of adequate antibiotic use were applied.
Antibiotic use at the moment the first positive blood cul-
ture was drawn was defined as adequate when administra-
tion of at least one antibiotic agent for which the P.
aeruginosa isolate is susceptible was given for at least 24 h
(adequate antibiotic use 1). In the 2 weeks after the blood
culture was drawn, antibiotic use was defined as adequate
when at least one administered antibiotic agent for which
the P. aeruginosa isolate is susceptible was administered
for at least 24 h (adequate antibiotic use 2). Patients who
deceased within 24 h after the first positive blood culture
were excluded from analyses with variable adequate anti-
biotic use 2. As third definition, we combined adequate
antibiotic use 1 and adequate antibiotic use 2 (adequate
antibiotic use total).
For all patients, we calculated the Charlson comorbid-
ity score at admission and for patients admitted to the
ICU we calculated the Acute Physiology And Chronic
Health Evaluation (APACHE) score within 24 h after ad-
mission to the ICU [16, 17]. The Charlson comorbidity
score is a method used to predict mortality by assigning
different weights to comorbidities [17]. We used an up-
dated Charlson comorbidity index which was validated
and published by Quan et al. in 2011 [17].
The primary endpoint of this study was 28-day in-
hospital all-cause mortality. Patients were followed until
1) in-hospital death up until 28 days after the first posi-
tive blood culture, 2) hospital discharge within 28 days
after the first positive blood culture, or 3) until day 28 if
still admitted by that time. Readmissions within 28 days
after the first positive blood culture were also considered
and data was used for analyses.
Microbiological methods
Blood cultures taken on clinical indication were proc-
essed in the laboratory using standard microbiological
methods (BACTEC system BD). Identification and sus-
ceptibility testing of Gram-negative aerobic bacilli were
performed using Vitek2 (bioMérieux, Marcy l’Etoile,
France). Since January 2013, the MALDI-TOF (Bruker
Daltonics, Bremen, Germany) was used for identifica-
tion. Breakpoints were in accordance to Clinical and La-
boratory Standards Institute (CLSI) guidelines until
August 27th 2013, thereafter European Committee on
Antimicrobial Susceptibility Testing (EUCAST) guide-
lines were used. In case of suspected growth of
carbapenemase-producing P. aeruginosa or multidrug-
resistant P. aeruginosa, an in-house polymerase chain re-
action (PCR) for detection of blaVIM on LightCycler 480
(Roche Diagnostics, Almere, The Netherlands) was per-
formed as previously described [18, 19].
Statistical analysis
To calculate differences in mortality, crude mortality of
patients with CS-PA was subtracted from crude mortal-
ity of patients with VIM-PA. Kaplan-Meier survival
curves were constructed for these 2 groups for 28-day
in-hospital survival. The log rank test was performed to
statistically compare the two curves. Univariate analyses
in order to compare survivors to non-survivors were
conducted using a t test, the independent samples me-
dian test or the Mann-Whitney U test when appropriate.
All analyses were performed using SPSS version 24 (IBM
Corp., Armonk, New York, USA). Concerning the multi-
variable analysis: because some patients were discharged
and readmitted within 28 days, a start-stop-event Cox-
proportional hazard model was fitted using the R project
for statistical computing, version 3.4.3 (Vienna, Austria)
to calculate hazard ratios (HRs) for 28-day in-hospital
mortality. The selection of variables in the multivariable
model was based on clinical relevance and results of the
univariate analysis, with age and sex as standard parame-
ters included. To test if the model improved when
relevant interaction terms were added, models were
compared using the ANOVA statistic (analysis of devi-
ance). P-values of < 0.05 were considered statistically sig-
nificant, and a 95% confidence interval (CI) was used.
Results
Patient inclusion and characteristics
Between 2004 and 2016, 249 patients with a P. aeruginosa
positive blood culture were included in this study (Fig. 1),
of which 40 (16.1%) were identified with VIM-PA, and
209 (83.9%) with CS-PA. In blood cultures of three pa-
tients, a CoNS was present in a single blood culture, which
was considered to be contamination (i.e. n = 1 Staphylo-
coccus epidermidis, n = 1 S. hominis, and n = 1 Staphylo-
coccus species). In another patient, a CoNS was found in a
second blood culture together with a P. aeruginosa, how-
ever, the two blood cultures taken on the same day were
negative, as well as a blood culture taken a few days later.
Furthermore, no antibiotics were started for this CoNS.
Therefore, this was also considered to be contamination.
Overall, 159 male (63.9%), and 90 (36.1%) female patients
were included, with a mean age of 59.5 years old. Regard-
ing age and sex, there were only small, non-significant dif-
ferences between survivors and non-survivors (Table 1).
Twenty-eight patients (11.2%) died within 48 h after the
positive blood culture, 11 with a VIM-PA bacteremia
(4.4% total, 27.5% of patients identified with VIM-PA),
and 17 with a CS-PA bacteremia (6.8% total, 8.1% of pa-
tients identified with CS-PA) (P-value < 0.001). Of these
patients, 4 with a VIM-PA bacteremia (1.6% total, 10.0%
of patients identified with VIM-PA), and also 4 patients
with a CS-PA bacteremia (1.6% total, 1.9% of patients
identified with CS-PA) died within 24 h (P-value = 0.008).
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For these 8 patients, analysis on adequate antibiotic use 2
could not be performed.
28-day in-hospital all-cause mortality
Fifty-eight (23.3%) out of 249 patients died within 28
days in the Erasmus MC, and 191 patients (76.7%) sur-
vived during follow-up. Seventeen out of 40 (42.5%) pa-
tients with VIM-PA died within 28 days in the Erasmus
MC, compared to 41 out of 209 (19.6%) patients with
CS-PA. Therefore, the difference in crude mortality rate
was 22.9%. Additionally, the Kaplan-Meier survival curve
visualizes the difference between patients identified with
VIM-PA compared to CS-PA over time (Log Rank P-
value = 0.001) (Fig. 2). Patients with VIM-PA deceased
shortly after the positive blood culture (median = 2 days,
range 0–20). This was sooner compared to patients with
CS-PA (median = 5 days, range 0–25). Univariate ana-
lyses showed that mortality was associated with a noso-
comial infection, having VIM-PA instead of CS-PA,
acquisition of the bacterium in the ICU, and inadequate
antibiotic therapy in total and at days 1–15 after the
positive blood culture (adequate AB therapy 2) (Table
1). The Charlson score was not associated with mortal-
ity, as was the APACHE score on admission to the ICU
(Table 1). Between patients identified with a VIM-PA or
CS-PA there were no significant differences regarding
the Charlson or the APACHE score.
In the multivariable model, the following variables
were included: (i) sex, (ii) age, (iii) VIM-PA vs. CS-PA,
(iv) ICU as ward of acquisition, (v) nosocomial
Fig. 1 Flow diagram of patient inclusion. Abbreviations: CoNS, coagulase-negative staphylococci; VIM-PA, Verona Integron-encoded Metallo-β-
lactamase-positive Pseudomonas aeruginosa; CS-PA, VIM-negative, carbapenem-susceptible Pseudomonas aeruginosa
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Table 1 Patient-related clinical variables of survivors and non-survivors
Characteristic Non-survivors
(n = 58)
Survivors
(n = 191)
P-value
Male gender (%) 38 (65.5) 121 (63.4) 0.764
Mean age ± SD at time of first blood culture with PA 60.5 ± 12.9 59.3 ± 14.1 0.539
Nosocomial infection (%) 45 (77.6) 113 (59.2) 0.011
VIM-PA bacteremia (%) 17 (29.3) 23 (12.0) 0.002
Nosocomial infection (%) 17 (100) 19 (82.6) 0.070
Adequate AB therapy 1 (%)a 5 (31.3) 8 (42.1) 0.818
Adequate AB therapy 2 (%)b 5 (38.5) 23 (100) < 0.001
Median Charlson score(range)c,d 2 (0–6) 3 (0–10) 0.639
Ward of acquisition; ICU (%) 29 (50) 32 (16.8) < 0.001
Median APACHE score (range)e 22 (10–43) 22.5 (7–41) 0.757
APACHE > 25 (%)e 6 (11.8) 7 (35.0) 0.588
Immunocompromisedf 29 (50.0) 84 (44.0) 0.420
Adequate AB therapy total (%)g,h 31 (63.3) 157 (98.1) < 0.001
Adequate AB therapy 1 (%)i 17 (30.9) 52 (27.8) 0.654
Adequate AB therapy 2 (%) 26 (52.0)h 156 (97.5)j < 0.001
Abbreviations: SD Standard deviation, PA Pseudomonas aeruginosa, VIM-PA Verona Integron-encoded Metallo-β-lactamase-positive Pseudomonas aeruginosa,
APACHE Acute Physiology and Chronic Health Evaluation, ICU Intensive care unit, AB Antibiotic; adequate AB therapy 1, day 0 for at least 24 h adequate AB use;
adequate AB therapy 2, days 1–14 adequate AB use, for at least 24 h. Bold P-values are significant
anon-survivors = 1 missing. bFour patients were excluded because they deceased within 24 h. cQuan et al. [17]. dCharlson: survivors = 1 missing, non-survivors = 1
missing. eAPACHE: survivors = 12 missing, non-survivors = 7 missing. fCombination of variables neutropenia; use of corticosteroids and use of immunosuppressive
agents other than corticosteroids. gAdequate AB total: survivors = 31 missing, non-survivors = 1 missing. hEight patients from the non-survivors were excluded
because they deceased within 24 h. iAdequate AB 1: survivors = 4 missing, non-survivors = 3 missing. jAdequate AB 2: survivors = 31 missing
Fig. 2 Kaplan Meier curve of patients with VIM-negative, carbapenem-susceptible Pseudomonas aeruginosa (dark-grey line) and patients with VIM-
positive Pseudomonas aeruginosa (light grey line). Y-axis, cumulative survival, X-axis, days. Log Rank P- value = 0.001
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acquisition of P. aeruginosa, (vi) adequate antibiotic use 1
and (vii) adequate antibiotic use 2. Figure 3 shows the re-
sults of the final multivariable model, in which acquisition
in the ICU was identified as a statistically significant risk
factor for mortality in all patients (HR = 3.32, 95%CI =
1.60 to 6.87). Having had adequate antibiotic therapy in
days 1–14 after the positive blood culture (adequate anti-
biotic use 2) was identified as a determinant for survival
(HR = 0.03, 95%CI = 0.01 to 0.06) (Fig. 3). Although
significantly associated in univariate analyses, VIM-PA vs.
CS-PA was not identified as an independent risk factor for
mortality, thus after correcting for all other variables
present in the model.
Discussion
The 28-day in-hospital all-cause mortality in patients
with a bacteremia with VIM-PA was significantly higher
compared to patients with a bacteremia with CS-PA,
with a difference in crude mortality rate of more than
22%. In the systematic review published by Zhang et al.
the attributable mortality ranged from 8 to 18.4%, with 4
studies included from Brazil, Spain, Korea and the U.S.
[2]. Thus, in our center in the Netherlands the rate is
high. Despite the difference in crude mortality between
VIM-PA and CS-PA, in the multivariable model VIM-
PA was not identified to be significantly associated with
mortality. This was also reported by Peña et al. They
described that the effect of resistance on mortality de-
creased with higher Charlson scores, i.e. the effect disap-
peared in the presence of comorbidities [1]. We did
identify that acquisition of P. aeruginosa in the ICU was
significantly associated with mortality, which could be
related to disease severity. However, in the univariate
analysis we did not identify any differences between sur-
vivors and non-survivors, and between patients with
VIM-PA and CS-PA regarding the Charlson score at
hospital admission or APACHE score on admission to
the ICU. The Charlson comorbidity score is obtained
with data from time of admission and may therefore not
represent the severity of disease during admission, espe-
cially not in a tertiary care hospital where patients need
and receive high level care; this includes broad-spectrum
antibiotics, several medical devices (e.g. mechanical ven-
tilation, central venous catheters) and close monitoring
by physicians and nurses. This makes these patients
more vulnerable for acquisition and infection by micro-
organisms, which could lead to mortality. Further-
more, acquisition of P. aeruginosa in the hospital
could be responsible for deterioration of the patients’
clinical condition.
Patients with VIM-PA deceased shortly after the posi-
tive blood culture, which was sooner compared to pa-
tients with CS-PA. A possible explanation could be that
more than half of patients with VIM-PA acquired this
bacterium in the ICU, compared to 17.2% of patients
with CS-PA. Acquisition in the ICU may therefore be an
indication of increased severity of disease at the moment
of acquisition. A second possible explanation could be
differences in receiving timely adequate antibiotic ther-
apy. Adequate antibiotic use 2 (i.e. days 1–14 after the
positive blood culture for at least 24 h) was identified as
a protective factor, which means that this decreased risk
of mortality. Survivors were two times more likely to re-
ceive correct antibiotic therapy than non-survivors
(97.5% vs. 52.0%, respectively). This is also described by
González et al., Paulsson et al., DiMondi et al., Peña
Fig. 3 Multivariable analysis to identify determinants significantly related to mortality after Pseudomonas aeruginosa bacteremia. Abbreviations:
ICU, intensive care unit; AB, antibiotic; HR, hazard ratio; 95%CI, 95% confidence interval; VIM-PA, Verona Integron-encoded Metallo-β-lactamase-
positive Pseudomonas aeruginosa; adequate AB therapy 1, day 0 for at least 24 h adequate AB use; adequate AB therapy 2, days 1–14 adequate
AB use, for at least 24 h
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et al. and Raman et al. [20–24]. This big difference and
very low percentage of correct antibiotic use in non-
survivors could be largely explained by the time of death:
78% of patients died between 24 and 48 h after the first
positive blood culture. In some cases, treatment with for
example meropenem was started, however not given for
> 24 h before the patient died. In other cases, an incor-
rect antibiotic was given e.g. for which the identified P.
aeruginosa was resistant, or no antibiotics were started.
Since VIM-PA in our patient group was found to be
resistant for several antibiotic classes, it can be hypothe-
sized that patients with a VIM-PA bacteremia have an
increased risk of receiving inadequate empirical anti-
biotic therapy. However, in our patient group there was
no difference in receiving adequate therapy 1, 2 or total
between patients with VIM-PA and CS-PA. A possible
explanation is that most patients with VIM-PA were in
the ICU when having a VIM-PA bacteremia, and in 52%
VIM-PA was acquired in the ICU. At the ICU, patients
are monitored very closely and screening cultures of
various sample-sites are taken regularly. Therefore,
colonization of VIM-PA in a patient may be detected be-
fore infection occurs, facilitating starting adequate ther-
apy when indicated. When comparing patients with
acquisition of P. aeruginosa in the ICU to patients with
acquisition in non-ICU wards, there was a difference in
receiving adequate antibiotic therapy 1 (ICU, 36.7%;
non-ICU, 25.8%), however this was not statistically sig-
nificant (P- value = 0.107).
Limitations and strengths
Our study has some limitations. First, patient groups
with VIM-PA and CS-PA were not matched. Ideally,
matching should have been done on life-expectancy
and/or severity of illness on the day of positive blood
culture. Second, this is a retrospective study conducted
in a single tertiary care hospital in the Netherlands;
therefore, the results may not be generalizable to other
institutions and/or countries. However, we feel that a
single center study design is preferred above a multi-
center when studying the sole effect of VIM presence
above other patient- and care-related risk factors, as the
latter differ considerably between centers. Third, because
of the low total number of deceased patients (n = 58),
small but true differences may have been missed.
A strength of our study is that despite it being a single
center study, a large group of patients could be included.
Second, we focused on solely the VIM gene.
Conclusions and implications
The crude mortality rate was significantly higher in pa-
tients with a VIM-PA bacteremia compared to patients
with a CS-PA bacteremia in our university hospital. Ac-
quisition of VIM-PA and CS-PA mainly occurred in the
ICU in a vulnerable ICU patient group, 51.7 and 31.3%
respectively. Additionally, patients deceased rapidly after
acquiring Pseudomonas aeruginosa. Despite the higher
crude mortality rate for VIM-PA, our study showed that
in our population bacteremia with CS-PA were equally
important regarding clinical outcome compared to VIM-
PA, since multivariable analyses showed no difference
between these two groups. Infections with CS-PA should
therefore not be underestimated. Adequate antibiotic
therapy for VIM-PA as well as for CS-PA has shown to
be a determinant for surviving. Therefore, since VIM-PA
are resistant to many antibiotic groups and consequently
more difficult to treat, awareness of the presence of
VIM-PA in the hospital environment and rapid micro-
biological diagnostics and sensitivity analysis are essen-
tial for timely administration of adequate antibiotics.
Acquisition of P. aeruginosa should be avoided and pre-
vented, in particular in the ICU, independent of resist-
ance profile. To elucidate the sole role of VIM we
propose to perform a multi-center study in different
countries with a design matched on life expectancy.
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